Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia

Serial studies have demonstrated that induction therapy with FLAM [flavopiridol (alvocidib) 50 mg/m(2) days 1–3, cytarabine 667 mg/m(2)/day continuous infusion days 6–8, and mitoxantrone (FLAM) 40 mg/m(2) day 9] yields complete remission rates of nearly 70% in newly diagnosed poor-risk acute myeloid...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Haematologica
Main Authors: Zeidner, Joshua F., Foster, Matthew C., Blackford, Amanda L., Litzow, Mark R., Morris, Lawrence E., Strickland, Stephen A., Lancet, Jeffrey E., Bose, Prithviraj, Levy, M. Yair, Tibes, Raoul, Gojo, Ivana, Gocke, Christopher D., Rosner, Gary L., Little, Richard F., Wright, John J., Doyle, L. Austin, Smith, B. Douglas, Karp, Judith E.
Format: Artigo
Sprog:Inglês
Udgivet: Ferrata Storti Foundation 2015
Fag:
Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4800702/
https://ncbi.nlm.nih.gov/pubmed/26022709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2015.125849
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker